DaVita
DVA
176.78
-3.62
-2.01%
DaVita
US · DVA
#1361 by market cap
Listed 1970
176.78
-3.62
-2.01%
Live - 5344 symbols - heartbeat 412s ago
· 2026-10-07 19:54
After-hours
176.78
0.00%
- Market cap
- 11.28B
- P/E (TTM)i
- 14.57
- P/Bi
- -14.74
- EPSi
- 9.84
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on DVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.61, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.46% YoY
Margins
- Gross margin
- 32.25%
- Operating margin
- 14.74%
- Net margin
- 5.47%
Key ratios & quality
- Enterprise valuei
- 21.28B
- PEG ratioi
- 1.45
- Altman Z-Scorei
- 1.61
PEG uses trailing P/E against the 3-year net income growth rate (10.04%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.40B | 11.39B | 11.55B | 11.62B | 11.61B | 12.14B | 12.82B | 13.64B |
| Gross profit | 3.21B | 3.47B | 3.56B | 3.65B | 3.40B | 3.82B | 4.22B | 4.40B |
| Selling & admin expenses | 1.14B | 1.10B | 1.25B | 1.20B | 1.36B | 1.47B | 1.54B | 1.67B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.49B | 1.76B | 1.68B | 1.77B | 1.31B | 1.60B | 1.95B | 2.01B |
| Pretax profit | 1.05B | 1.20B | 1.32B | 1.52B | 966.28M | 1.18B | 1.53B | 1.35B |
| Tax | 258.40M | 279.63M | 313.93M | 306.73M | 198.09M | 220.12M | 279.66M | 293.11M |
| Net profit | 333.04M | 1.02B | 994.68M | 1.21B | 781.64M | 956.98M | 1.25B | 1.08B |
| Basic EPS | 1 | 5 | 6 | 9 | 6 | 8 | 11 | 10 |
| Diluted EPS | 0.92 | 5.27 | 6.31 | 8.90 | 5.85 | 7.42 | 10.73 | 9.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.22B | 3.38B | 3.42B | 3.62B | 3.42B | 3.55B |
| Gross profit | 983.87M | 1.12B | 1.09B | 1.21B | 1.07B | 1.16B |
| Selling & admin expenses | 374.09M | 412.81M | 414.37M | 472.36M | 421.91M | 423.46M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 433.33M | 530.48M | 495.61M | 551.21M | 473.55M | 570.82M |
| Pretax profit | 286.33M | 368.93M | 308.80M | 382.76M | 341.23M | 435.01M |
| Tax | 54.12M | 93.71M | 68.55M | 76.73M | 66.20M | 91.79M |
| Net profit | 232.22M | 275.22M | 240.25M | 331.03M | 275.04M | 343.22M |
| Basic EPS | 2 | 3 | 2 | 3 | 3 | 4 |
| Diluted EPS | 2.00 | 2.58 | 2.04 | 3.29 | 2.87 | 4.02 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 8.42B | 3.69B | 3.15B | 3.17B | 3.16B | 3.14B | 3.75B | 4.06B |
| Cash & ST investments | 325.97M | 1.11B | 345.06M | 484.21M | 321.78M | 391.67M | 846.00M | 700.74M |
| Inventory | 107.38M | 97.95M | 111.63M | 107.43M | 109.12M | 143.11M | 134.56M | 160.63M |
| Total assets | 19.11B | 17.31B | 16.99B | 17.12B | 16.93B | 16.89B | 17.29B | 17.48B |
| Total current liabilities | 4.89B | 2.37B | 2.48B | 2.40B | 2.62B | 2.64B | 2.97B | 3.14B |
| Short-term debt | 1.93B | 474.62M | 538.04M | 573.39M | 626.81M | 517.70M | 681.28M | 534.69M |
| Long-term debt | 8.17B | 7.98B | 7.92B | 8.73B | 8.69B | 8.27B | 9.18B | 10.16B |
| Total liabilities | 14,077,213,000.00 | 13,811,776,000.00 | 14,091,736,000.00 | 14,750,508,000.00 | 14,703,452,000.00 | 14,150,228,000.00 | 15,193,917,000.00 | 16,321,665,000.00 |
| Total equity | 5.03B | 3.50B | 2.90B | 2.37B | 2.22B | 2.74B | 2.09B | 1.16B |
| Retained earnings | 2.74B | 1.43B | 852.54M | 354.34M | 174.49M | 598.29M | 1.53B | -328.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.64B | 4.09B | 4.11B | 4.06B | 4.06B | 4.19B |
| Cash & ST investments | 511.94M | 739.43M | 736.48M | 700.74M | 666.55M | 688.88M |
| Inventory | 150.52M | 146.30M | 139.09M | 160.63M | 141.61M | 151.54M |
| Total assets | 17.12B | 17.49B | 17.56B | 17.48B | 17.50B | 17.71B |
| Total current liabilities | 2.91B | 2.93B | 3.02B | 3.14B | 2.87B | 2.86B |
| Short-term debt | 599.15M | 611.69M | 494.94M | 534.69M | 544.87M | 556.67M |
| Long-term debt | 9.56B | 10.08B | 10.18B | 10.16B | 10.51B | 10.66B |
| Total liabilities | 15,459,061,000.00 | 15,939,935,000.00 | 16,215,170,000.00 | 16,321,665,000.00 | 16,451,199,000.00 | 16,630,051,000.00 |
| Total equity | 1.66B | 1.55B | 1.34B | 1.16B | 1.05B | 1.08B |
| Retained earnings | 1.70B | 1.90B | 2.05B | -328.43M | -179.24M | 81.23M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.77B | 2.07B | 1.98B | 1.93B | 1.56B | 2.06B | 2.02B | 1.89B |
| Depreciation & amortization | 591.04M | 615.15M | 630.44M | 680.62M | 732.60M | 745.44M | 723.86M | 715.35M |
| Free cash flow | 784.50M | 1.31B | 1.30B | 1.29B | 961.14M | 1.49B | 1.47B | 1.31B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.15B | -2.37B | -1.46B | -1.60B | -783.65M | -272.22M | -1.39B | -1.79B |
| Ending cash balance | 415.42M | 1.21B | 501.79M | 554.96M | 338.99M | 464.63M | 879.83M | 757.75M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 180.01M | 324.24M | 841.53M | 540.73M | 320.83M | 490.07M |
| Depreciation & amortization | 176.45M | 174.70M | 177.49M | 186.70M | 177.83M | 167.81M |
| Free cash flow | 36.75M | 203.15M | 675.44M | 395.30M | 218.81M | 320.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -541.85M | -452.25M | -470.08M | -328.83M | -396.31M | -364.35M |
| Ending cash balance | 524.57M | 796.96M | 795.41M | 757.75M | 726.40M | 751.86M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 3.80 | 27.79 | 43.99 | 91.48 | 76.36 | 78.21 | 159.08 | -- |
| ROA %i | 0.84 | 4.45 | 4.51 | 5.74 | 3.29 | 4.09 | 5.48 | 4.30 |
| ROIC %i | 3.79 | 8.49 | 7.77 | 9.53 | 6.68 | 8.22 | 10.67 | -- |
| 5-year avg ROE %i | 11.39 | 13.93 | 21.66 | 36.26 | 48.68 | 63.57 | 89.82 | -- |
| EBIT margin %i | 13.47 | 14.39 | 14.05 | 15.52 | 11.40 | 12.98 | 15.61 | 14.12 |
| FCF / sales %i | 6.88 | 11.47 | 11.29 | 11.10 | 8.28 | 12.28 | 11.44 | 9.61 |
| Current ratioi | 1.72 | 1.56 | 1.27 | 1.32 | 1.20 | 1.19 | 1.26 | 1.29 |
| Quick ratioi | 0.56 | 1.44 | 1.12 | 1.21 | 1.10 | 1.06 | 1.14 | 1.16 |
| Debt / assetsi | 52.86 | 64.56 | 65.89 | 69.94 | 69.84 | 65.80 | 69.81 | 73.65 |
| LT debt / equityi | 220.68 | 501.61 | 770.18 | 1,509.17 | 1,571.71 | 1,003.57 | 9,400.07 | -- |
| Interest coveragei | 3.15 | 3.69 | 5.33 | 6.32 | 3.71 | 3.95 | 4.25 | 3.32 |
| Revenue CAGR (3Y) %i | 4.54 | 2.08 | 2.02 | 0.62 | 0.64 | 1.67 | 3.32 | 5.53 |
| Net income CAGR (3Y) %i | -16.08 | -2.68 | 5.25 | 83.10 | -11.59 | -3.67 | -1.46 | 10.04 |
| FCF CAGR (3Y) %i | -2.61 | 4.54 | 8.98 | 18.01 | -9.71 | 4.56 | 4.39 | 10.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 260.92 | 635.30 | -- | -- | -- | -- |
| ROA %i | 4.98 | 4.85 | 4.40 | 4.30 | 4.51 | 4.81 |
| ROIC %i | 10.25 | 10.34 | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.04 | 15.17 | 14.63 | 14.12 | 14.40 | 14.72 |
| FCF / sales %i | 13.57 | 9.79 | 9.70 | 9.61 | 10.79 | 11.49 |
| Current ratioi | 1.25 | 1.39 | 1.36 | 1.29 | 1.42 | 1.47 |
| Quick ratioi | 1.12 | 1.28 | 1.23 | 1.16 | 1.28 | 1.33 |
| Debt / assetsi | 71.97 | 73.26 | 72.79 | 73.65 | 75.55 | 75.70 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 3.86 | 3.60 | 3.42 | 3.32 | 3.38 | 3.47 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- United States (US) dialysis is the largest reported line at 84.74% of revenue, across 3 reported segments.
- The next-largest line, Other - Ancillary services, is a distant second at 15.66% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
United States (US) dialysis84.74%
Other - Ancillary services15.66%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.